Global Antibiotic Research & Development Partnership

Recent papers from Global Antibiotic Research & Development Partnership

1. Reviving antibiotic innovation - Tackling the AMR brain drain to rebuild the global antimicrobial R&D community2026
2. Exploring the evidence for use of cefiderocol as part of combination therapies: a systematic review of in vitro, in vivo, and clinical studiesJournal of Global Antimicrobial Resistance · 2026
3. A systematic review and individual patient data meta-analysis to determine the effect of primaquine dose on efficacy, tolerability and safety in uncomplicated Plasmodium vivax malaria in Latin AmericaThe Lancet Regional Health - Americas · 2026
4. Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistanceThe Lancet · 2024
5. In vitro activity of flomoxef, fosfomycin and amikacin versus a global panel of third-generation cephalosporin-resistant Enterobacterales and prediction of their ability in pairwise combinations to work as carbapenem-sparing regimensJournal of Global Antimicrobial Resistance · 2026
6. Identifying pediatric extrapulmonary tuberculosis through an active screening program: Findings and programmatic implications from BangladeshPLOS Global Public Health · 2026
7. ICH E21: from landmark guidance to specific action for maternal and child healthJournal of Translational Medicine · 2026
8. In vitro activity of zoliflodacin against Neisseria gonorrhoeae collected in the United States from 2020 to 2022Antimicrobial Agents and Chemotherapy · 2026
9. Drug stock-outs in HIV, tuberculosis, and malaria programs: a systematic reviewEClinicalMedicine · 2026
10. Expedited research and approval of medicines for drug-resistant bacterial infections in children.2026
11. Local prevalence of ceftriaxone resistance informs optimal deployment of new gonorrhea treatmentsOpen Forum Infectious Diseases · 2026
12. Assessing N. gonorrhoeae prevalence and testing capacity for new treatment rollout: a scoping review for Cambodia, Thailand, Vietnam and South AfricaBMC Infectious Diseases · 2026
13. Diagnostics for priority bacterial pathogens: global gaps and research needs for curbing antimicrobial resistance in low-resource settingsThe Lancet Microbe · 2026
14. Increasing detection of individuals with tuberculosis through engagement of informal health care providers in Northeastern NigeriaBMC Public Health · 2026
15. Microbiological analysis and whole-genome sequencing of Neisseria gonorrhoeae from the microbiological failures in the international, zoliflodacin, phase 3, clinical trial for treatment of uncomplicated urogenital gonorrhoea: a retrospective, genomic, observational studyThe Lancet Microbe · 2026
16. Evaluation of Drug-Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants.2026
17. AntibioticDB: An Updated and Improved Open-Access Database for the Antibacterial Research and Development CommunityACS Infectious Diseases · 2026
18. P-1207. In Vitro Activity of Zoliflodacin against Neisseria gonorrhoeae Isolates Collected in 2022 from The United StatesOpen Forum Infectious Diseases · 2026
19. Subgroup Analyses of Microbiological Cure Rates by Baseline Zoliflodacin MIC and Susceptibility to Ciprofloxacin in Participants from the Global Zoliflodacin Phase 3 Randomized Controlled TrialOpen Forum Infectious Diseases · 2026
20. P-1206. Association of Sex Assigned at Birth and Sexual Orientation with Antimicrobial Susceptibility of Baseline Neisseria gonorrhoeae Isolates from Participants Recruited in the Global Zoliflodacin Phase 3 Randomized Controlled TrialOpen Forum Infectious Diseases · 2026